Cautionary Note Regarding Forward-Looking Statements

Statements in this presentation may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including those regarding WuXi’s anticipated 2008 biologics and total net revenue; the timing of and the costs and benefits of the restructuring; and WuXi’s plans to expand and to continue growth for its biologics testing, cell banking and cell therapy services.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. For example, it may take longer than anticipated to wind down the biologics manufacturing business; actual restructuring charges could be higher; and actual cost savings could be less than anticipated and it may take longer than anticipated to realize those cost savings. In addition, the biologics, testing, cell banking and cell therapy services may not continue to grow at historical rates or at all. For example, WuXi’s ability to successfully expand and to attract customers for these biologics services may be harmed by the winddown of the Philadelphia-based biologics manufacturing operations.

Other relevant factors include: uncertainty in the global economy may adversely impact our business and the trends for outsourced R&D and manufacturing; pharmaceutical and biotechnology companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and we may be unable to expand our capabilities successfully to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include: our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this presentation should be read in conjunction with the consolidated and pro forma financial statements and notes thereto included in our 2007 Annual Report on Form 20-F filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see “Risk Factors” beginning on Page 10 of our 2007 Annual Report on Form 20-F. Any projections in this presentation are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation. Such information speaks only as of the date of this presentation.
Use of Non-GAAP Financial Measures

WuXi PharmaTech has provided the third quarter 2007 and 2008 net income and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses and amortization of acquired intangible assets. The Company believes both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company’s financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The Company expects to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis going forward.

Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP measures to non-GAAP measures for the indicated periods attached hereto.
Who is WuXi PharmaTech?

- A leading global pharmaceutical, biotech, and medical device R&D outsourcing company
- Operations in both China and the United States
- Provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process
- Services designed to assist our global partners in shortening the time and lowering the cost of drug and medical device R&D
History of Expansion

- **2000**: Incorporated
- **2001-2002**: Established discovery chemistry and FTE-based services
- **2003**: Established process development services
- **2004**: Established bioanalytical operation
- **2005**: Opened Tianjin R&D campus
- **2006**: Started expansion of manufacturing plant
- **2007**: Established toxicology and formulation services
- **2008**: Acquired AppTec Laboratory Services, Inc., changed operating company name to WuXi AppTec
- **2003-2004**: Began offering manufacturing services
- **2007**: Established service biology operation
- **2008**: Began offering integrated services
Record of Strong Revenue and Income Growth

(US$ in Millions)

Growth in capabilities has brought solid growth in net revenue and net income.
WuXi’s Service Offerings

Testing:
- Biologics
- Medical Devices
- Bioanalytic Services

- Chemistry and Medicinal Chemistry
- Service Biology
- Toxicology
- Process Research
- Formulation

Laboratory Services

Two Reporting Lines:
1. Laboratory Services
2. Manufacturing Services

Manufacturing
- API
- Advanced Intermediates
Laboratory Services Revenue

Total Net Revenue

(US$ in Millions)

- 2004: 16.4
- 2005: 29.4
- 2006: 59.8
- 2007: 102.4
- 9M07: 73.5
- 9M08: 130.7

- 1Q07: 21.7
- 2Q07: 25.1
- 3Q07: 26.7
- 4Q07: 28.8
- 1Q08: 38.5
- 2Q08: 45.2
- 3Q08: 47.0
Manufacturing Revenue

Total Net Revenue

(US$ in Millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>1Q07</th>
<th>2Q07</th>
<th>3Q07</th>
<th>4Q07</th>
<th>1Q08</th>
<th>2Q08</th>
<th>3Q08</th>
<th>9M07</th>
<th>9M08</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>4.5</td>
<td>4.4</td>
<td>10.1</td>
<td>32.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20.5</td>
<td>64.7</td>
</tr>
</tbody>
</table>
WuXi PharmaTech’s Value Proposition

- Experienced International Management Team
- Highly Educated and Trained Workforce
- Broad Technical Expertise
- Operational Excellence
- World-Class Facilities in China and the United States
- Intense Focus on a Diversified, High-Quality Customer Base
- Flexible Contractual Approach
- Strong Protection of Customers’ Intellectual Property
Management Team with Broad International Experience

- Chairman/CEO with Ph.D. in organic chemistry from Columbia University and a founding scientist at Pharmacopeia

- Senior management also includes:
  - Leaders with significant work experience at Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Genentech, Guidant, ImClone Systems, Mallinckrodt, Merck, Novartis, Pfizer, Pharmacopeia, Rhone Poulenc, Schering-Plough, SmithKline Beecham, Tanox, TargeGen, Wellcome Biotech, Wyeth, McKinsey, PriceWaterhouse Coopers, and Deloitte
  - Ph.D.’s/M.D.’s from Columbia, Dartmouth, Harvard, NYU, Northwestern, and Yale
  - More than 100 U.S.-educated scientist returnees
**Highly Educated and Rapidly Growing Workforce**

- Young, vibrant workforce
- Highly sought-after employer on college campuses in China
- Scientists predominantly have Master’s degrees and above
- Proprietary training program produces superior scientists

<table>
<thead>
<tr>
<th>Year</th>
<th>Employees</th>
<th>Scientists</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>48</td>
<td>27</td>
</tr>
<tr>
<td>2002</td>
<td>128</td>
<td>83</td>
</tr>
<tr>
<td>2003</td>
<td>252</td>
<td>160</td>
</tr>
<tr>
<td>2004</td>
<td>533</td>
<td>332</td>
</tr>
<tr>
<td>2005</td>
<td>890</td>
<td>560</td>
</tr>
<tr>
<td>2006</td>
<td>1,244</td>
<td>1,244</td>
</tr>
<tr>
<td>2007</td>
<td>2,770</td>
<td>2,106</td>
</tr>
<tr>
<td>2008</td>
<td>3,739</td>
<td>2,717</td>
</tr>
</tbody>
</table>
WuXi Is Transforming Traditional Drug Discovery R&D Paradigm

Traditional In-House Paradigm

- Number of researchers on projects
- Research projects
- Fewer compounds going through R&D process
- Lower success rate of INDs

WuXi Paradigm

- Flexible and expandable capacity
- Larger throughput
- Faster and better yield of INDs
- More and better clinical candidates realized through operational excellence and expandable capacity

Capacity limits and inflexibility result in time and cost inefficiencies

Larger capacity and more data yield better compounds, thereby shortening the time to market
Fully Integrated Global Platform

Our Mission: To provide fully integrated R&D services to improve the success of research and shorten the time of development.
World-Class Facilities in China

- 800,000 ft² R&D facility for chemistry, bioanalytical services, service biology, and process research in Shanghai
- 130,000 ft² R&D facility for chemistry in Tianjin
- 220,000 ft² cGMP-quality process development and manufacturing plant in Jinshan
- 323,450 ft² GLP preclinical drug safety evaluation center under construction in Suzhou
World-Class Facilities in the United States

- 75,000 ft² FDA-registered facility in Philadelphia for cell banking, cell biology, molecular biology, virology, analytical services, and viral clearance studies
- 63,000 ft² FDA-registered facility in St. Paul for *in vitro* and *in vivo* biocompatibility, toxicology, contract cGMP manufacturing, and processing for tissue-based products
- 46,000 ft² FDA-registered facility in Atlanta for microbiology, medical device chemistry, sterilization validations, and package testing
The World’s Leading Pharmaceutical and Biotech Companies as Customers

- AstraZeneca
- gsk
- MERCK
- Pfizer
- AMGEN
- Bristol-Myers Squibb
- Novartis
- Lilly
- Genentech
- sanofi aventis
- Johnson & Johnson
- Schering-Plough
- biogen idec
- Mitsubishi Pharma Corporation
- vitae
- MILLENNIUM

> 80 small-molecule customers, > 600 large-molecule and medical-device customers

Nine of the world’s ten largest pharmaceutical companies
Recognition as the Leading R&D Collaborator

- Repeat business from each of the Top 10 customers over the last four years
- Expanding services, longer and larger customer contracts

- “Best in Class Outsourced R&D in Pharma and Biotech” from Frost & Sullivan in 2008
- “Outstanding Strategic Collaboration Award” from AstraZeneca in 2007
- “Outstanding Collaboration Award” from Novartis in 2007
- “Chemistry CRO of the Year” from Pfizer in 2008
- “Outstanding Collaboration Award” from Novartis in 2007
- “Chemical Product R&D Preferred Partner” from Lilly in 2006
Flexible Contract Structures to Meet Customer Needs

**FTE (Full-Time Equivalent) Contract**
- Contracted scientist becomes exclusive to the customer
- WuXi ensures compliance with standards
- Customer and WuXi leaders manage deliverables
- Popular with large pharmaceutical customers
- Represents majority of China-based laboratory services

**Fee-for-Service Contract**
- WuXi manages workflow and utilization
- Payment made upon delivery of contracted service
- Popular with life sciences companies managing cash reserves
- Represents majority of testing and manufacturing services
Evolution of Partnership Models

From tactical to strategic outsourcing relationships

Operational and Service Excellence

Transaction

- Responsive to requests

Preferred Supplier

- Established core team
- Builds collaborative mechanisms
- Develops understanding of client’s business

Executive Relationships

- Incorporates client into strategic planning
- Assigns dedicated relationship manager
- Makes directed investments
- Builds strong collaborative mechanisms

Strategic Service Integration

Strategic Alliance

- Shares common goals/objectives
- Engages in joint strategic planning
- Relationship-based structure
- Makes open-ended agreements
- New business forms

Source: PWC
With a relationship spanning five years, WuXi now has dedicated three floors to the customer’s R&D outsourcing needs.
Nine-Month Financial Results Reflect Success of WuXi’s Strategies for Growth

Non-GAAP figures exclude share-based compensation expenses, amortization of acquired intangible assets and deferred tax impact on acquired intangible assets.

<table>
<thead>
<tr>
<th>Revenues:</th>
<th>2008</th>
<th>2007</th>
<th>% Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Services</td>
<td>130.7</td>
<td>73.5</td>
<td>78%</td>
</tr>
<tr>
<td>Manufacturing Services</td>
<td>64.7</td>
<td>24.6</td>
<td>163%</td>
</tr>
<tr>
<td>Total Net Revenues</td>
<td>195.4</td>
<td>98.1</td>
<td>99%</td>
</tr>
<tr>
<td>Non-GAAP Gross Profit</td>
<td>81.7</td>
<td>48.7</td>
<td>68%</td>
</tr>
<tr>
<td>Non-GAAP Operating Income</td>
<td>48.5</td>
<td>27.1</td>
<td>79%</td>
</tr>
<tr>
<td>Non-GAAP Net Income</td>
<td>45.6</td>
<td>28.0</td>
<td>63%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>61.0</td>
<td>34.2</td>
<td>78%</td>
</tr>
<tr>
<td>Diluted Earnings Per ADS</td>
<td>0.63</td>
<td>0.44</td>
<td>42%</td>
</tr>
</tbody>
</table>
Increased Collaboration Drives Diversified Revenue Growth

Revenue from top 10 customers grows rapidly as WuXi expands its services.

Other customers, including those of AppTec, also contribute significantly to revenue growth.

Reaching New Customers and Deepening Existing Relationships
Impact from Current Market Conditions Has Been Manageable

Comments by other CRO players indicate potential for reduced demand for early development services, due to:

- Fewer new project initiations
- Project delays
- Shift of pharmaceutical budgets to later-stage and clinical services

To date, WuXi has not seen project delays or cancellations in laboratory services from significant customers

The impact on manufacturing has been manageable

As a profoundly customer-driven company, we are prepared to adjust to customers’ needs and to manage expenses accordingly
2009 Strategic Initiatives

- Expand and strengthen WuXi’s core laboratory services
  - Expand medicinal chemistry and integrated drug discovery and development business
  - Refocus Philadelphia to build profitable testing business

- Establish GLP toxicology capability
  - Complete construction of Suzhou toxicology facility
  - Conduct non-GLP services while establishing GLP quality system
  - Initiate and expand training to develop large pool of skilled staff
  - Expect revenues in late 2009, strong trajectory in 2010 and beyond

- Start up commercial API manufacturing in China
  - Complete construction and validation of the facility
  - Begin staged opening of facility
  - Expand production to meet customer demand
2009 Initiatives on Behalf of Investors

- Strengthen dialogue with Wall Street through greater outreach
- Increase transparency of the business with new metrics
- Improve predictability of forecasting
Market Dynamics Provide Strong Growth Opportunities for WuXi

(US$ in billions)

Global Drug Discovery Outsourcing Market

Global R&D Spending

Source: Kalorama Information
WuXi’s Strategy is Succeeding

- Pharmaceutical business model is changing
- Growing demand for outsourced development and manufacturing services
- WuXi has built a strong reputation for:
  - High-quality services
  - Cost-effectiveness
  - Efficiency to save partners time
  - Integration of services from bench to market
  - Strong intellectual property protection
  - Proven ability to grow customer contracts
- Company delivering strong current revenue and profitability growth
  - 98% revenue and 70% adjusted EBITDA growth Q308/Q307
- WuXi is well positioned for the long term
  - Expanding capacity and capabilities to meet customers’ expanding needs
At WuXi PharmaTech, We Are Determined to Serve You Better
Dr. Ge Li
Founder, Chairman, and CEO

27th Annual JPMorgan Healthcare Conference
### GAAP to Non-GAAP Reconciliation

<table>
<thead>
<tr>
<th>3Q2008 (US$ in millions)</th>
<th>GAAP</th>
<th>Share-Based Compensation Expenses</th>
<th>Amortization of Acquired Intangible Assets</th>
<th>Non-GAAP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Revenues:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Services</td>
<td>47.0</td>
<td></td>
<td>24.2</td>
<td>47.0</td>
</tr>
<tr>
<td>Manufacturing Services</td>
<td>20.5</td>
<td></td>
<td>15.9</td>
<td>20.5</td>
</tr>
<tr>
<td>Total Net Revenues</td>
<td>67.5</td>
<td></td>
<td>67.5</td>
<td>67.5</td>
</tr>
<tr>
<td><strong>COGS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Services</td>
<td>27.6</td>
<td>(0.6)</td>
<td>(2.8)</td>
<td>24.2</td>
</tr>
<tr>
<td>Manufacturing Services</td>
<td>17.1</td>
<td>***</td>
<td>(1.2)</td>
<td>15.9</td>
</tr>
<tr>
<td>Total COGS</td>
<td>44.7</td>
<td>(0.6)</td>
<td>(4.0)</td>
<td>40.1</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>22.8</td>
<td>0.6</td>
<td>4.0</td>
<td>27.4</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>13.8</td>
<td>(2.5)</td>
<td></td>
<td>11.3</td>
</tr>
<tr>
<td>Operating Income</td>
<td>9.0</td>
<td>3.1</td>
<td>4.0</td>
<td>16.1</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>13%</td>
<td></td>
<td></td>
<td>24%</td>
</tr>
</tbody>
</table>

- Non-GAAP figures exclude share-based compensation expenses, amortization of acquired intangible assets and deferred tax impact on acquired intangible assets.
- *** Less than $0.1M
GAAP & Non-GAAP ADS Results (in Millions of US$)

<table>
<thead>
<tr>
<th>GAAP Results</th>
<th>Three Months Ended September 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Income attributable to holders of ADS</td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>7,267</td>
</tr>
<tr>
<td>Diluted</td>
<td>7,267</td>
</tr>
<tr>
<td>Basic earnings per ADS</td>
<td>0.11</td>
</tr>
<tr>
<td>Diluted earnings per ADS</td>
<td>0.10</td>
</tr>
<tr>
<td>Weighted average ADS outstanding - basic</td>
<td>64,531,068</td>
</tr>
<tr>
<td>Weighted average ADS outstanding - diluted</td>
<td>72,931,421</td>
</tr>
</tbody>
</table>

Cash & Cash Equivalents on 9-30-08: $73.3 million

<table>
<thead>
<tr>
<th>Non-GAAP Results</th>
<th>Q1 2008</th>
<th>Q2 2008</th>
<th>Q3 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-GAAP net income</td>
<td>$ 17.3</td>
<td>$ 15.5</td>
<td>$ 12.8</td>
</tr>
<tr>
<td>Weighted average ADS outstanding - diluted</td>
<td>72,416,243</td>
<td>72,949,790</td>
<td>72,931,421</td>
</tr>
<tr>
<td>Non-GAAP net income per ADS</td>
<td>$ 0.24</td>
<td>$ 0.21</td>
<td>$ 0.18</td>
</tr>
</tbody>
</table>

1 ADS = 8 ordinary shares